AMGN AMGEN INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 318154 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.2%
TTM net income YoY34.1%
TTM EPS YoY33.4%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR7.5%
Margins
Gross margin70.9%
Operating margin32.4%
Net margin24.1%
FCF margin24.6%
EBITDA margin39.4%
Returns
ROE78.4%
ROA10.1%
ROIC (approx.)19.5%
Asset turnover0.42x
Leverage & solvency
Liabilities / assets85.1%
Debt / equity3.76x
Current ratio1.48x
Interest coverage4.78x
Cash quality & payout
Operating cash flow / net income1.28x
Accruals ratio-2.8%
Payout ratio57.1%
Capex / revenue6.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $36.75B | $33.42B |
| Cost of revenue | $12.04B | $12.86B |
| Gross profit | $24.71B | $20.57B |
| R&D expense | $7.27B | $5.96B |
| SG&A expense | $7.05B | $7.10B |
| Operating income | $9.08B | $7.26B |
| Interest expense | $2.75B | $3.15B |
| Pretax income | $8.98B | $4.61B |
| Income tax | $1.26B | $519.00M |
| Net income | $7.71B | $4.09B |
| EBITDA | $14.25B | $12.85B |
| EPS (basic) | 14.33 | 7.62 |
| EPS (diluted) | 14.23 | 7.56 |
| Dividends declared per share | 9.66 | 9.13 |
| Weighted avg. shares (diluted) | 542.00M | 541.00M |
| Balance sheet | ||
| Cash & equivalents | $9.13B | $11.97B |
| Receivables | $9.57B | $6.78B |
| Inventory | $6.22B | $7.00B |
| Current assets | $29.06B | $29.03B |
| PP&E, net | $7.91B | $6.54B |
| Goodwill | $18.68B | $18.64B |
| Intangibles | $22.28B | $27.70B |
| Total assets | $90.59B | $91.84B |
| Current liabilities | $25.49B | $23.10B |
| Short-term debt | $4.60B | $3.55B |
| Long-term debt | $50.01B | $56.55B |
| Total debt | $54.60B | $60.10B |
| Total liabilities | $81.93B | $85.96B |
| Shareholders' equity | $8.66B | $5.88B |
| Net debt | $45.48B | $48.13B |
| Shares outstanding | 538.80M | 536.90M |
| Cash flow statement | ||
| Operating cash flow | $9.96B | $11.49B |
| Capital expenditure | $1.86B | $1.10B |
| Free cash flow | $8.10B | $10.39B |
| Investing cash flow | -$1.94B | -$1.05B |
| Financing cash flow | -$10.86B | -$9.41B |
| Depreciation & amortization | $5.17B | $5.59B |
| Stock-based compensation | $494.00M | $530.00M |
| Dividends paid | $5.12B | $4.83B |
| Share buybacks | $0 | $200.00M |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.